Biovitrum AB, the Swedish drug development firm spun out of Pharmacia Corp., entered one of Europe's landmark biotechnology deals of 2003, a pact with Amgen Inc. to develop small-molecule, selective inhibitors of 11beta-hydroxysteroid dehydrogenase 1 for Type II diabetes and other metabolic diseases. (BioWorld International)

ZGene Raises DKK15M To Push Gene Therapy Platform

Sep. 10, 2003

By Cormac Sheridan

Ireland Will Not Oppose Funding For Stem Cell Work, Minister Says

Sep. 10, 2003

By Cormac Sheridan

ZGene Raises DKK15M To Push Gene Therapy Platform

Sep. 10, 2003

By Cormac Sheridan

Biovitrum Lands Blockbuster With Amgen For Diabetes Drug

Sep. 10, 2003

By Cormac Sheridan

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...